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Abstract
Recent epidemiological studies indicate bisphenol-A (BPA), an estrogenic chemical used in 
production of epoxy, polycarbonate and plastic may increase risk of insulin resistance and type 2 
diabetes. Exposure to BPA during pregnancy may contribute to development of gestational 
diabetes mellitus (GDM), a precursor to type 2 diabetes in women. This pilot study examined the 
association between BPA exposure, fasting blood glucose levels (FBG) and GDM diagnosis 
during pregnancy. Banked urine samples from 22 cases of GDM and 72 controls were analyzed 
for total (free BPA + conjugates) urinary BPA concentrations (μg/L). FBG levels (mg/dl) were 
obtained from 1 h 50 g glucose tolerance tests (GTT) that women underwent for routine GDM 
screening (mean gestational age=26.6 weeks sd=3.8). Those with an initial screening value ≥135 
mg/dl underwent 3-hr 100 g oral GTT. GDM diagnoses were made when the initial screening 
value was ≥ 200 mg/dl or when values at ≥ 2 time points exceeded 3-hr oral GTT thresholds. 
Among controls, median FBG levels (mg/dL) did not differ across exposure tertiles, defined 
according to the distribution of total specific-gravity adjusted urinary BPA concentrations. 
Logistic regression models controlling for race/ethnicity did not provide evidence of association 
between BPA exposure and case status across increasing tertiles of BPA exposure (number of 
GDM cases/controls in tertile 1: 13/24, tertile 2: 6/24 tertile 3: 3/24).. Findings do not support a 
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relationship between total urinary BPA concentrations and altered glucose metabolism during 
pregnancy. However, due to study limitations findings need to be interpreted with caution.
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Introduction
Several epidemiological studies have linked diabetes mellitus and exposure to endocrine 
active compounds such as dioxin (Cranmer et al., 2000), polychlorinated biphenyls 
(Longnecker et al., 2001; Vasiliu et al., 2006; Wang et al., 2008), phthalates (Lind et al., 
2012; Stahlhut et al., 2007; Svensson et al., 2011) and most recently bisphenol-A (BPA) 
(Lang et al., 2008). Human exposure to bisphenol-A (BPA), an estrogenic chemical used in 
the production of epoxy resins and polycarbonate plastics is widespread (Kang et al., 2006; 
Kasper-Sonnenberg et al., 2012; Shin et al., 2010). Initially thought to be a weak 
environmental estrogen, evidence now indicates that low dose exposures to BPA may elicit 
cellular responses with effects in various types of tissues that are just as efficacious and 
potent as estradiol (Welsons et al., 2003, 2006; Wozniak et al., 2006). Estradiol 
concentrations outside the normal range have been shown to disrupt glucose homeostasis 
and perhaps contribute to the risk of developing type 2 diabetes mellitus (Barros et al., 2006; 
Ding et al., 2007; Godsland, 1996; Godsland, 2005; Livingstone and Collison, 2002; Nadal 
et al., 2008). By mimicking estradiol, BPA was also found to adversely alter glucose 
homeostasis by targeting estrogen receptors henceforth disrupting pancreatic beta cell 
function (Alonso-Magdalena et al., 2005; 2006; 2010a; 2010b; Mauvais-Jarvis, 2011; 
Ropero et al., 2008). Animal studies using mice demonstrated that a single low level 
exposure to BPA (10 μg/kg) administered subcutaneously (sc) increased plasma insulin, and 
prolonged exposure elevated pancreatic beta cell insulin content provoking postprandial 
hyperinsulinemia and insulin resistance (Alonso-Magdalena et al., 2006; Ropero et al., 
2008). A recent study in pregnant mice, administered BPA sc on days 9–16 of gestation 
demonstrated an association between BPA exposure, glucose intolerance and increased 
plasma insulin during pregnancy and 4 months postpartum. (Alonso-Magdalena et al., 
2010b). It was therefore hypothesized that exposure to BPA during pregnancy may 
contribute to development of GDM by mimicking the actions of estradiol and disrupting 
glucose homeostasis. This pilot study used banked urine specimens from an existing (parent) 
case-control study of GDM to assess the association between total urinary BPA levels 
during pregnancy, blood glucose levels and diagnosis of GDM.
Methods
Participants in the parent case-control study were recruited from the University of Oklahoma 
Medical Center Women’s and High Risk Pregnancy clinics located in Oklahoma City, 
Oklahoma between August 2009 and May 2010. The study and subsequent analyses were 
approved by the University of Oklahoma Health Sciences Center (OUHSC)’s Institutional 
Review Board. Clinical lab reports were reviewed to identify all pregnant women screened 
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at OUHSC Women’s Clinic for GDM. Patients who were referred to the OUHSC High Risk 
Pregnancy Clinic for the diagnosis of GDM (n=65) were recruited during their first post-
diagnostic visit. Controls (n=244) were selected concurrently from eligible obstetrical 
patients in the OUHSC Women’s Clinic who screened negative for GDM. Women were 
eligible to participate in the parent study if (1) they resided in one of 9 counties 
predominately served by the clinics (Oklahoma, Kingfisher, Logan, Lincoln, Pottawatomie, 
Cleveland, Canadian, McClain and Grady counties), (2) were 18 years of age or older, (3) 
had no pre-existing diagnosis of Type 1 or 2 diabetes mellitus, and (4) spoke English or 
Spanish. The sample size for this pilot study was limited by the amount of seed grant funds 
available to support the cost of lab analyses. Thus, a sub-sample of 22 cases and 72 controls 
was selected from subjects who consented to the banking of their specimens for future 
research and who self-reported their race as Hispanic, Non-Hispanic White or Non-Hispanic 
Black. The characteristics of the cases and controls in the sub-sample did not differ 
significantly from cases and controls in the parent study with respect to age, race/ethnicity, 
income and obesity.
Urine specimens were collected at enrollment in sterile polypropylene containers and stored 
in sterile 2 ml polypropylene cryovials at −20°C. Specimens were shipped in dry ice to the 
Institute for Prevention and Occupational Medicine of the German Social Accident 
Insurance - Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany. Total (free 
BPA + conjugates) and free urinary BPA concentrations were determined using a high 
performance liquid chromatography – mass spectrometry method (on line SPE HPLC – 
MS/MS) with isotope dilution described previously (Koch et al., 2012). The limit of 
quantification (LOQ) for both total and free BPA was 0.1μg/L. Levels reported below the 
limit of detect (LOQ) (n=5), were imputed by dividing the LOQ by the square root of two 
(Hornung and Reed, 1990). A random subsample of specimens (n=34) underwent LC-
LC/MS-MS without enzymatic hydrolysis to measure free BPA concentrations. 
Quantification of free BPA in the subsample did not indicate BPA contamination or sample 
degradation in the pre-analytical phase or during sample collection and storage. Specimens 
were adjusted for urinary dilution using creatinine concentrations (μg/g) reported by the 
analytical lab (Lauwerys and Hoet, 2001) and specific gravity (μg/L) measured at the time of 
collection using a calibrated hand-held refractometer. Total urinary BPA concentrations 
among women without GDM (control group) were used to categorize BPA exposure into 
tertiles (e.g., specific-gravity (SG) adjusted BPA: ≤0.66 μg/L, >0.66 to <1.44 μg/L and ≥ 
1.44 μg/L). Exposure tertiles were created for unadjusted, creatinine and SG-corrected total 
urinary BPA concentrations. The associations between BPA exposure and GDM were also 
explored using total urinary BPA concentrations that were categorized into low levels (less 
than the median, specific-gravity adjusted BPA: <1.36 microgram/L) or high levels (greater 
than or equal to the median specific-gravity adjusted BPA: ≥1.36 microgram/L). Results 
from models are presented where BPA exposure was modeled using tertiles because 
findings did not vary using other exposure cutoffs.
Blood glucose levels for all participants were obtained from a 1 hr 50 g oral glucose 
challenge test (OGTT) routinely administered to screen pregnant women for GDM. Those 
with an initial screening value of 135–199 mg/dl underwent a 3 hr 100 g OGTT for 
diagnosis of GDM. A clinical diagnosis of GDM was made when the initial screening value 
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was ≥ 200 mg/dl or when the 3 hr 100 OGTT values at ≥ 2 time points exceeded 
recommended thresholds (Carpenter and Coustan, 1982; Metzger and Coustan (Eds) 1998). 
Blood glucose levels obtained from the 1 hr 50 g OGTT were used to assess the relationship 
between blood glucose levels and BPA exposure.
A questionnaire administered at the time of enrollment collected information on covariates 
of interest including demographic factors such as age, race/ethnicity, educational level, and 
annual household income, parity, previous diagnosis of GDM and family history of type 2 
diabetes mellitus. Prior to urine collection, participants were also asked to report the number 
of hr since last meal and the number of canned goods or beverages consumed in the previous 
24 hr. The interviewer also recorded the time of urine collection. Pre-pregnancy body mass 
index (BMI) (kg/m2) was calculated using self-reported height and weight. Gestational age 
at enrollment (weeks) was calculated by subtracting the self-reported date of the last 
menstrual period from the date of enrollment and dividing the number of days by 7. To 
evaluate maternal smoking as a confounder, urinary cotinine concentrations ≤ 15 ng/ml were 
used to define an active smoker (Benowitz et al., 2009a, 2009b).
All statistical analyses were conducted using SAS version 9.1.3 and performed for 
unadjusted (μg/L), creatinine (μg/g) and SG corrected (μg/L) total urinary BPA 
concentrations. Results of analyses by BPA standardization technique were generally similar 
and therefore only results for SG-corrected BPA concentrations are presented, unless 
otherwise noted. Geometric mean concentrations, 95% confidence intervals and distribution 
percentiles of total BPA urinary concentrations were calculated for GDM cases and controls. 
Categorical patient characteristics including BPA exposure were summarized and compared 
separately for GDM cases and controls using the Chi-square test of independence. Mann-
Whitney tests were used to compare 1) continuous patient characteristics by case status and 
2) median BPA urinary concentrations between categories of demographic characteristics.
Logistic regression was used to model the odds of higher levels of total urinary BPA among 
GDM cases compared to controls (using lowest tertile as the reference group), while 
controlling for covariates of interest. Confounding of the association between BPA exposure 
and GDM diagnoses was assessed for all covariates. A logistic regression model was created 
for GDM diagnosis with each BPA exposure variable and a given potential confounder. Due 
to the small number of GDM cases confounding for each covariate was assessed separately. 
Confounding was assessed by evaluating the change (>20%) in the crude and the adjusted 
odds ratios when controlling for the covariate in the model (Miettinen, 1976). Race/ethnicity 
(Hispanic, non-Hispanic) was the only factor that met the criteria for confounding in these 
analyses and this factor was controlled for in the final models. There were no active smokers 
among GDM cases. Thus, analyses were also repeated after restricting cases (n=22) and 
controls (n=51) to women who were not active smokers. Parameter estimates did not differ 
when compared to those obtained when including all women regardless of smoking status; 
therefore results from the complete data are reported here.
Analyses examining the association between total urinary BPA concentrations and blood 
glucose levels were restricted to controls (n=72). Blood glucose levels were log transformed 
to normalize the distribution of the residuals. Multiple linear regression was used to model 
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log blood glucose levels by tertiles of total urinary BPA concentrations controlling for 
potential confounders. Confounding was assessed using the methods previously described. 
However, to determine whether changes in log blood glucose due to adjustment were 
clinically relevant, parameter estimates from crude and adjusted models were back 
transformed and then compared to assess the absolute and relative increase in blood glucose 
levels for BPA exposure tertiles. No covariates met the criteria for confounding in the linear 
regression models.
Results
Demographic characteristics were found to differ by GDM case status (Table 1). Cases of 
GDM tended to be older, have higher BMI, and were more frequently overweight or obese 
than controls. There was an important discrepancy in the ethnic distribution with about two-
thirds of the cases being Hispanic compared to one-quarter of controls. An examination of 
lifestyle factors and reported medical history also revealed differences between GDM cases 
and controls. No GDM cases were categorized as being active smokers; thus, smoking 
among controls was more prevalent. The majority of GDM cases and controls reported 
having at least one family member with type 2 diabetes mellitus. Median gestational age at 
the time of GDM screening and at time of study enrollment did not differ significantly by 
case status.
The total BPA urinary concentrations of GDM cases and controls were low. Table 2 lists the 
geometric means, 95% confidence intervals and distribution percentiles by GDM case status 
for total urinary BPA concentrations adjusted and unadjusted for urinary dilution. Specific 
gravity-corrected geometric mean (GM) total BPA concentrations among cases (GM=0.8 
ng/L, 95% CI: 0.5, 1.1) were numerically lower than among controls (GM=1.67 ng/L, 95% 
CI: 1.01, 2.32). Among GDM cases, SG-corrected total urinary BPA concentrations (ng/L) 
did not significantly differ across characteristics examined (Table 3). Among the control 
group, median urinary BPA concentrations differed between categories of BMI, education 
and ethnicity. No significant associations were observed between BPA exposure categories 
and GDM diagnosis (Table 4). In addition, when considering control participants, linear 
regression models did not identify a significant relationship between mean log blood glucose 
levels and BPA exposure categories (data not shown).
Discussion
This study is the first to explore associations between BPA exposure during pregnancy, 
blood glucose levels and physician diagnosis of GDM. This study was not able to 
demonstrate an association between total urinary BPA concentrations and blood glucose 
levels, or diagnosis of GDM in a low income and racially diverse pregnant population. 
These findings are in accordance with a review showing no adverse affects on human health 
at biologically relevant doses of BPA exposure (Willhite et al., 2008) and a study in mother-
child pairs showing that less than 16% of circulating levels was free of active BPA (Kasper-
Sonnenberg et al., 2012). A recent cross-sectional study of US adult men and women 
(n=1455) using data obtained from the 2003–2004 National Health and Nutrition 
Examination Survey (NHANES) found associations between BPA exposure, fasting blood 
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glucose levels and self-reported diagnosis of diabetes mellitus (DM). After controlling for 
age, gender, race/ethnicity, education, income, BMI, waist circumference and urinary 
creatinine, the odds of self-reported DM diagnosis (type 1 and type 2) was 1.39 (95% CI, 
1.21–1.60) fold higher with a 1 standard deviation elevation in total urinary BPA 
concentration. This study reported that log transformed fasting glucose levels rose with a 1-
SD increase in BPA urinary concentration, when adjusted for age, race/ethnicity and urinary 
creatinine (β=0.02, 95% CI, 0.00, 0.03) (Lang et al., 2008).
These contradictory results are most likely attributed to differences in study populations and 
sample size. Our study was conducted in pregnant women and the outcome of interest was 
GDM, not type 1 or type 2 diabetes mellitus. Unlike the previous study where self-reported 
diabetes may be more susceptible to misclassification error, participants in this study 
underwent screening for GDM and further testing was used to confirm GDM diagnosis. 
Further, the association between low levels of BPA and diagnosis of GDM was examined 
using categories of BPA exposure based on distribution percentiles. In this study, total 
urinary BPA concentrations among pregnant women were observed to be at least two-fold 
lower than those reported in pregnant women in the US (Braun et al., 2011; Harley et al., 
2013), Netherlands (Ye et al., 2008) and Spain (Casas et al., 2011). Although results were 
robust to different exposure cut points, our small sample size limited statistical power to 
detect modest associations and may have also hindered our ability to comprehensively 
explore and control for confounders. Despite the differences in characteristics observed 
between GDM cases and controls, only race/ethnicity was found to be a confounder when 
examining the association between BPA and GDM diagnosis. Therefore, results need to be 
interpreted cautiously.
Exposure assessment may not have occurred at the etiologically relevant time window for 
GDM. Therefore, misclassification of exposure may account for the null associations 
observed between total BPA concentrations and GDM. BPA exposure was based on a single 
spot urine sample collected at the time of GDM screening during the second trimester of 
pregnancy. Several studies documenting within-person variability of total BPA urinary 
concentrations reveal that a single sample may be an inadequate assessment of BPA 
exposure and may lead to misclassification of exposure (Mahalingaiah et al., 2008; Stahlhut 
et al., 2009). BPA is quickly metabolized in the body and therefore, total urinary BPA 
concentrations may reflect at most exposure to BPA in the last 24 hr (Stahlhut et al., 2009). 
A study conducted among men and women undergoing infertility evaluation and treatment 
measured specific gravity-adjusted BPA in at least 3 urine samples from each participant, 
with a mean of 172 days between the first and last collection days (Mahalingaiah et al., 
2008). The detected sensitivity and specificity of a single urine sample in predicting whether 
a subject was in the highest tertile of BPA exposure was moderate (0.64 and 0.76). A more 
recent study of BPA variability in pregnant women (n=389) obtained three spot urine 
samples at mean gestational ages (±SD) of 16±2, 26±2 and 39±1.8 weeks (Braun et al., 
2011). The study found low reproducibility of BPA measurements using unadjusted (intra 
class correlation coefficient (ICC) = 0.25) and creatinine-corrected total urinary BPA 
concentrations (ICC=0.10). The findings also indicated that unadjusted and creatinine-
corrected concentrations varied by time of day, decreasing from early morning through 
midmorning and increasing again in the afternoon (Braun et al., 2011). It was possible to 
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collect information regarding factors that might account for differences in BPA exposure 
among GDM cases and controls. Prior to spot urine collection, GDM cases and controls 
were not found to differ in the number of hr since last meal, the number of canned goods or 
beverages consumed in the previous 24 hr or time of urine specimen collection.
Conclusions
In this small pilot study it was not possible to demonstrate an association between BPA 
exposure and development of GDM. Larger studies are needed to assess whether 
environmental contaminants such as BPA play a role in the etiology of GDM. Exposure 
assessment in future studies would be improved by using repeated specimen collection to 
measure BPA during etiologically relevant windows for GDM and other outcomes of 
interest. Such investigations are warranted to identify environmental exposures that may 
impact the health of vulnerable populations, including pregnant women and their offspring.
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Table 1
Distribution of demographic and clinical characteristics of cases of gestational diabetes mellitus (GDM) and 
their controls in Oklahoma
Cases (n=22) Controls (n=72) p-value
Age (years) n (%) n (%)
 ≥25 17 (77) 34 (47) 0.010c
 Median (Range) 29.0 (19, 35) 24.0 (18, 42) 0.009e
Body Mass Index (kg/m2)
 ≥25 18 (82) 33 (46) 0.003 c
 Median (Range) 29.5 (21.6, 58.9) 24.5 (16.8, 44.6) 0.004e
Race/Ethnicity
 Hispanic 14 (64) 20 (28) 0.002 c
Income
 <$10,000 per year 7 (32) 40 (56) 0.051 c
Education
 <High School 16 (73) 21 (29) 0.0003 c
Active Smoker
 Yes 0 (0) 15 (21) 0.003d
Family History of Type 2 DMa
 Yes 18 (82) 38 (53) 0.053d
Previous GDM Diagnosisb
 Yes 8 (42) 1 (2) <0.0001d
Parity
 Nulliparous 4 (18) 22 (31) 0.256 c
Gestational Age (weeks) Median (Range) Median (Range)
 at GDM Screen 25.9 (9.7, 32.9) 26.6 (22.3, 34.43) 0.08e
 at Enrollment 29.5 (16.9, 34.7) 30.6 (26.0, 38.1) 0.16e
Blood Glucose Levels (mg/l)
163.5 (137, 269) 109.0 (69, 197) <0.0001e
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a
Analysis omitted two controls with unknown family history of type 2 diabetes mellitus
b
Analysis omitted cases (n=4) and controls (n=22) pregnant for the first time
c
Chi-Square Test of Independence p-value
d
Fisher’s Exact p-value for Chi-Square Test of Independence
e
Mann Whitney test p-value
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Table 4
Odds ratios and 95% confidence interval for association between specific-gravity adjusted bisphenol-A (BPA) 
exposure variables and diagnosis of gestational diabetes mellitus (GDM)a
Cases (n=22) Controls (n=72) OR (95% CI)
BPA Tertile Model
Tertile 1 (reference) 13 24 --
Tertile 2 6 24 0.58 (0.18, 1.19)
Tertile 3 3 24 0.37 (0.09, 1.60)
a
Models adjusted for race/ethnicity
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